Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance.

Journal of the advanced practitioner in oncology·2026
Same author

Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

AI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignancies.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.

Haematologica·2025
Same author

The Role of CELMoD Agents in Multiple Myeloma.

OncoTargets and therapy·2025
Same author

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.

The Journal of clinical investigation·2025
Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026
Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026
Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026
Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026
Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026
Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Improving induction therapy in multiple myeloma.

Ajay Nooka1, Charise Gleason, Sagar Lonial

  • 1Emory University, Building C, Room 4004, 1365 Clifton Road, Atlanta, GA 30322, USA.

Current Hematologic Malignancy Reports
|May 8, 2010
PubMed
Summary
This summary is machine-generated.

Recent advances in multiple myeloma induction therapy have improved outcomes for transplant-eligible and ineligible patients. Optimal regimen selection is crucial, with triplet therapies showing superior results, though deeper responses are still sought.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jun 13, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Multiple myeloma treatment has evolved significantly over the last decade.
  • Novel agents have transformed therapeutic strategies for both transplant-eligible and ineligible patients.
  • Transplant eligibility is a key factor in determining induction therapy approach.

Purpose of the Study:

  • To review recent advancements in multiple myeloma induction therapy.
  • To discuss the impact of novel agents on treatment strategies.
  • To highlight the evolving landscape of induction regimens based on transplant eligibility.

Main Methods:

  • Review of current literature and clinical practice guidelines.
  • Analysis of treatment outcomes for various induction regimens.
  • Evaluation of novel agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors.

Main Results:

  • Triplet therapies incorporating IMiDs and proteasome inhibitors have become standard for both transplant-eligible and ineligible patients.
  • Quadruplet therapies show efficacy with acceptable toxicity but require further investigation.
  • Postinduction response significantly impacts overall survival, underscoring the importance of regimen choice.

Conclusions:

  • Induction therapy for multiple myeloma has seen substantial progress, with triplet regimens offering superior outcomes.
  • Achieving deeper molecular remissions and optimizing risk stratification in induction therapy remain key challenges.
  • Continued research is needed to refine treatment strategies and improve patient outcomes in multiple myeloma.